Imaging active blood clots using PET technology
Molecular Imaging of Active Venous Thrombus With Positron Emission Tomography (PET)
This study is testing a new way to use PET scans to see active blood clots in people with conditions like deep vein thrombosis and pulmonary embolism, to help doctors decide who really needs blood-thinning treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Trial ID | NCT06057844 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the diagnostic accuracy of venous thromboembolism (VTE), which includes conditions like deep vein thrombosis and pulmonary embolism. It focuses on utilizing positron emission tomography (PET) to visualize active venous thrombi directly, contrasting with traditional imaging techniques that only show the effects of obstructions. By marking the thrombus, the study seeks to better identify patients who require anticoagulant treatment and avoid unnecessary long-term therapy for those who do not. The approach involves additional blood sampling to enhance the imaging process.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are voluntary blood donors without significant medical histories affecting coagulation.
Not a fit: Patients under 18 years old, those with chronic health issues, or those currently on anticoagulant or anti-platelet therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of VTE, ensuring appropriate treatment for patients and reducing unnecessary medication.
How similar studies have performed: While traditional imaging techniques are well-established, this novel approach using PET for direct thrombus visualization has not been widely tested, making it a potentially groundbreaking method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Major patient (≥18 years), voluntary blood donor, with no notable medical history altering coagulation (i.e. known thrombophilia, active cancer), no chronic pathology, no current treatment. Exclusion Criteria: Minor patient (\<18 years); known chronic pathology; long-term treatment including anti-platelet aggregation therapy or anticoagulant treatment, refusal to participate.
Where this trial is running
Brest
- Etablissement francais du sang — Brest, France (Recruiting)
Study contacts
- Study coordinator: Philippe ROBIN
- Email: philippe.robin@chu-brest.fr
- Phone: +33(0)298223327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.